CATT 2-year results add fuel to Avastin/Lucentis debate, with implications for Eylea
This article was originally published in Scrip
Updated results from a US government-funded study showed that long-term treatment with either Genentech's Lucentis (ranibizumab) or the much cheaper Avastin (bevacizumab) resulted in similar levels of visual improvement in patients with advanced age-related macular degeneration (AMD) – with clarity of vision with monthly treatments only slightly better than the as-needed (PRN) treatment group.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.